| answer text |
<p>Following intensive work with industry, the broad supply position for glucagon-like
peptide-1 receptor agonists (GLP-1 RAs) in the United Kingdom has improved. However,
global supply issues remain with specific medicines, including Victoza (liraglutide).
We issued updated guidance to healthcare professionals in the form of a National Patient
Safety Alert on the 3 January 2024 on how to manage patients requiring these medicines,
with input from expert clinicians. We continue to work closely with manufacturers
and others working in the supply chain to help ensure the continued supply of GLP-1
RAs for UK patients, and to resolve the remaining supply issues as quickly as possible,
for example by asking suppliers to expedite deliveries.</p><p>We know how distressing
and frustrating medicine supply issues can be, and the Department will continue to
help ensure that these critical medicines reach diabetes patients. If any patient
is concerned about their treatment, they should discuss this with their clinician
at the earliest opportunity.</p>
|
|
